ESSA Pharma Inc
NASDAQ:EPIX
ESSA Pharma Inc
NASDAQ:EPIX
Price:
6.95 USD
4.98%
Market Closed
Updated:
May 3, 2024
ESSA Pharma Inc
Interest Income Expense
|
ESSA Pharma Inc
Interest Income Expense Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Interest Income Expense
$6.1m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Interest Income Expense
$18.5m
|
CAGR 3-Years
36%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Interest Income Expense
$13.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Interest Income Expense
$4.1m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Interest Income Expense
$14.2m
|
CAGR 3-Years
112%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Interest Income Expense
-CA$3.2m
|
CAGR 3-Years
-373%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ESSA Pharma Inc's Interest Income Expense?
Interest Income Expense
6.1m
USD
6.1m
USD
Based on the financial report for Dec 31, 2023, ESSA Pharma Inc's Interest Income Expense amounts to 6.1m USD.
What is ESSA Pharma Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
131%
131%
Over the last year, the Interest Income Expense growth was 110%. The average annual Interest Income Expense growth rates for ESSA Pharma Inc have been 131% over the past three years .
You don't have any saved screeners yet
